Evidence map›Paper›PMID 41087667›Full record

ArticleBiological trace element research2026

Study on the Antifibrotic Property of Biogenic Zinc Oxide Nanoparticles Using Coriolus versicolor in the Rat Liver Failure Model.

Remya M, Raguvaran R, Siddharth Chaudhary, Karikalan M, Haritha C V, Madhu C L, Abhishek Chandra Saxena, Vadapalli Deekshita, Nerella Venkata Pavan Kumar, Shanmugarathinam A

Abstract read
PubMed Publisher
In one paragraph

Article in Biological trace element research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Heavy metal levels in malignant salivary gland tumours: a case-control study.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Remya MDivision of Medicine, ICAR-IVRI, Bareilly, 243122, UP, India.
Raguvaran RDivision of Medicine, ICAR-IVRI, Bareilly, 243122, UP, India. raguivri@gmail.com.
Siddharth ChaudharyDivision of Medicine, ICAR-IVRI, Bareilly, 243122, UP, India.
Karikalan MDivision of Pathology, ICAR-IVRI, Bareilly, 243122, UP, India.
Haritha C VDivision of Pharmacology, ICAR-IVRI, Bareilly, 243122, UP, India.
Madhu C LDivision of Pharmacology, ICAR-IVRI, Bareilly, 243122, UP, India.
Abhishek Chandra SaxenaDivision of Surgery, ICAR-IVRI, Bareilly, 243122, UP, India.
Vadapalli DeekshitaDivision of Pathology, ICAR-IVRI, Bareilly, 243122, UP, India.
Nerella Venkata Pavan KumarDivision of Pharmacology, ICAR-IVRI, Bareilly, 243122, UP, India.
Shanmugarathinam ADepartment of Pharmaceutical Technology, Bharathidasan Institute of Technology, Anna University, Tiruchirappalli, Tamil Nadu, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver fibrosis, a complex chronic disease, needs effective treatment to prevent cirrhosis and liver damage. Conventional therapy is ineffective due to inadequate delivery to liver cells and associated risks of toxicity and drug resistance, necessitating the development of innovative treatment approaches. The current study innovatively synthesized ZnO nanoparticles from Coriolus versicolor fungal extract and evaluated their antifibrotic properties, offering a promising approach for liver fibrosis treatment. We successfully synthesized ZnO NPs using zinc nitrate hexahydrate and Coriolus versicolor extract at 65 °C and 450 rpm for 4 h. This ZnO NPs exhibited an optimal particle size of 289 nm, moderate PDI of 0.615, and zeta potential of - 12.8 mV. UV spectroscopic analysis showed a strong absorbance peak at 341 nm in UV spectroscopic analysis and also revealed characteristic ZnO nanoparticles formation in SEM, FTIR, and XRD. In vivo study, Wistar rats were divided into five groups: healthy control, disease control (CCl

Indexed as

Liver CirrhosisNanoparticlesTrametesZinc OxideAnimalsAntioxidantsDisease Models, AnimalLiverMaleParticle SizeRatsRats, WistarAntioxidantsZinc OxideCoriolus versicolorGreen synthesisLiver fibrosisNanotechnologyZnO nanoparticles

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.